Table 1 Characteristics of MYC and MYC −... | American Society of Hematology

Table 1

Characteristics of MYC⁺ and MYC⁻ DLBCL patients

Feature	MYC⁺, n (%) (n = 12)	MYC⁻, n (%) (n = 123)	P
Median age, y	68	61	—
Age > 60 y	8 (67)	68 (55)	.448
Male sex	9 (75)	73 (59)	.289
Stage 3 or 4	6 (50)	75 (61)	.459
B symptoms
Extranodal any site	8 (67)	72 (58)	.584
Extranodal > 1	4 (33)	25 (20)	.295
Bone marrow	0	11 (9)	.280
Testicular	2 (17)	3 (2)	.013
Sinus	0	2 (1.6)	.280
Gastrointestinal	2 (17)	19 (15)	.911
Kidney	0	2 (1.6)	.656
Liver	0	7 (6)	.396
Bulky disease*	4 (33)	31 (26)	.575
PS > 2*	5 (42)	42 (36)	.677
LDH abnormal*	9 (75)	54 (50)	.100
LDH > 2× ULN	3 (25)	28 (26)	.930
IPI 0-2 vs 3-5	6 (50)	48 (39)	.459
Ki-67†
More than 80%	7 (58)	27 (22.5)	.007
More than 90%	6 (50)	9 (7.5)	< .001
More than 95%	4 (12)	8 (6.7)	.002
BCL2 protein⁺‡	8 (67)	86 (70)	.782
GCB phenotype§	7 (58)	61 (51)	.640

Feature	MYC⁺, n (%) (n = 12)	MYC⁻, n (%) (n = 123)	P
Median age, y	68	61	—
Age > 60 y	8 (67)	68 (55)	.448
Male sex	9 (75)	73 (59)	.289
Stage 3 or 4	6 (50)	75 (61)	.459
B symptoms
Extranodal any site	8 (67)	72 (58)	.584
Extranodal > 1	4 (33)	25 (20)	.295
Bone marrow	0	11 (9)	.280
Testicular	2 (17)	3 (2)	.013
Sinus	0	2 (1.6)	.280
Gastrointestinal	2 (17)	19 (15)	.911
Kidney	0	2 (1.6)	.656
Liver	0	7 (6)	.396
Bulky disease*	4 (33)	31 (26)	.575
PS > 2*	5 (42)	42 (36)	.677
LDH abnormal*	9 (75)	54 (50)	.100
LDH > 2× ULN	3 (25)	28 (26)	.930
IPI 0-2 vs 3-5	6 (50)	48 (39)	.459
Ki-67†
More than 80%	7 (58)	27 (22.5)	.007
More than 90%	6 (50)	9 (7.5)	< .001
More than 95%	4 (12)	8 (6.7)	.002
BCL2 protein⁺‡	8 (67)	86 (70)	.782
GCB phenotype§	7 (58)	61 (51)	.640

PS indicates Performance Status; LDH, lactic dehydrogenase; and ULN, upper limit of normal.

Missing data: LDH, n = 15; bulky disease, n = 3; PS, n = 5.

Failed in 3 MYC⁻ cases.

Results using the Dako antibody; not available in 1 MYC⁻ case.

Not available in 4 MYC⁻ cases.